Search research articles
Contact Us
Filters
Showing results (41-50 of 66) with videos related to
Page
of 7
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN
|
June 13, 2025
Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative Glomerulonephritis
Malak Ghaddar, Fernando Caravaca-Fontán, Manuel Praga, et al.
Kidney International
|
January 23, 2019
Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Jürgen Floege, Sean J Barbour, Daniel C Cattran, et al.
Kidney International
|
January 22, 2026
A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy
Mark Canney, Sana Shan, Lee Er, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
July 20, 2023
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
Sean J Barbour, Fernando C Fervenza, Dilshani Induruwage, et al.
Kidney International
|
November 21, 2020
Updating the International IgA Nephropathy Prediction Tool for use in children
Sean J Barbour, Rosanna Coppo, Lee Er, et al.
Kidney International
|
August 2, 2024
Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy
Sean J Barbour, Rosanna Coppo, Lee Er, et al.
Kidney International
|
January 8, 2021
Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression
Izabella Z A Pawluczyk, Athanasios Didangelos, Sean J Barbour, et al.
Diabetes, Obesity & Metabolism
|
April 28, 2022
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND
Taha Sen, Rosalie Scholtes, Peter J Greasley, et al.
Kidney International
|
December 17, 2013
Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy
Taewoo Lee, Andrea K Biddle, Sofia Lionaki, et al.
The Lancet. Diabetes & Endocrinology
|
June 20, 2020
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
David Z I Cherney, Claire C J Dekkers, Sean J Barbour, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 66) with videos related to
Sort By:
Page
of 7
Clinical Journal of the American Society of Nephrology : CJASN
|
June 13, 2025
Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative Glomerulonephritis
Malak Ghaddar, Fernando Caravaca-Fontán, Manuel Praga, et al.
Kidney International
|
January 23, 2019
Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Jürgen Floege, Sean J Barbour, Daniel C Cattran, et al.
Kidney International
|
January 22, 2026
A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy
Mark Canney, Sana Shan, Lee Er, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
July 20, 2023
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
Sean J Barbour, Fernando C Fervenza, Dilshani Induruwage, et al.
Kidney International
|
November 21, 2020
Updating the International IgA Nephropathy Prediction Tool for use in children
Sean J Barbour, Rosanna Coppo, Lee Er, et al.
Kidney International
|
August 2, 2024
Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy
Sean J Barbour, Rosanna Coppo, Lee Er, et al.
Kidney International
|
January 8, 2021
Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression
Izabella Z A Pawluczyk, Athanasios Didangelos, Sean J Barbour, et al.
Diabetes, Obesity & Metabolism
|
April 28, 2022
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND
Taha Sen, Rosalie Scholtes, Peter J Greasley, et al.
Kidney International
|
December 17, 2013
Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy
Taewoo Lee, Andrea K Biddle, Sofia Lionaki, et al.
The Lancet. Diabetes & Endocrinology
|
June 20, 2020
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
David Z I Cherney, Claire C J Dekkers, Sean J Barbour, et al.
Page
of 7